

Mainz advanced adenoma biomarkers feasibility study results

Aug. 7, 2023—[Mainz Biomed](#) announced results of an independent feasibility study conducted in collaboration with members of the National Cancer Institute's Early Detection Research Network to evaluate the company's portfolio of five mRNA biomarkers, which it acquired from Université de Sherbrooke, Quebec.

Results from the study found that Mainz's proprietary nucleic acid extraction and PCR processes are robust and highly reliable, able to consistently obtain DNA and mRNA from patient specimens that were stored for more than 15 years. In addition, the company said that two of the biomarkers were able to detect signals from samples of patients with colorectal cancer that had higher levels of CRC-specific transcripts and from specimens of patients with advanced adenoma, in which CRC-specific transcripts are fewer and harder to detect.

ColoAlert, the company's flagship product, is an at-home, early-detection diagnostic test for colorectal cancer based on real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples. The test is CE marked; Mainz is running a pivotal FDA clinical study for U.S. regulatory approval.